Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEVENAZA: Reduced vs Continuous Venetoclax with Azacitidine in AML
NCT07082452Phase 3Not yet recruiting
- Sponsor
- Gustave Roussy
- Start
- Sep 2025
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Proportion of subjects with complete remission or complete remission with incomplete marrow recovery at 3 years. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07082452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082452.